NRS Stroke Research Network Research Study Summaries
Top of page
ACUTE research is when a patient admitted to hospital having had a stroke is asked to take
part in research that might involve a new stroke treatment.
ARTSS2
ECASS 4 Extend
ENCHANTED
EuroHYP-1
FOCUS
GOLD 2.2
LINCHPIN
MICA
PATCH
PISTE
RTEASE
TARDIS
TITCH 2
WAKE-UP
PREVENTION research increases understanding of what causes a stroke to happen and
improves the prevention of stroke in routine clinical practice – using a broad range of
research techniques.
CROMIS2
CVR Lacunar Stroke Study v1.0
ECST-2
Gluteal biopsy in CADASIL
RESTART
XILO-FIST - NEW
-1-
,REHABILITATION stroke studies aim to restore functional recovery and to facilitate patients
and their carers to lead the lives they wish.
ACCESS
BIG CACTUS
EVERLAP – NEW
Examining a 'life after stroke' help sheet for stroke survivors – NEW
Long term consequences and recovery from stroke: what is important to stroke survivors
and health professionals?
MELLO
NON INVASIVE BRAIN STIMULATION IN STROKE PATIENTS - NEW
OSPREy
RATULS
TEARS
TREAT UI
SOCLE II
-2-
,ACUTE STUDIES
Back to top
Study Title ARTSS2
A pilot, phase IIb, randomised, multi-center trial of
Argatroban in combination with recombinant tissue
plasminogen activator for acute stroke
Study Type Acute
Lay Summary A pilot, phase IIb, randomised, multicentre trial of
Argatroban in combination with recombinant tissue
plasminogen activator for acute stroke. Recombinant
tissue plasminogen activator (rtPA), the only proven
treatment for acute ischemic stroke, fails to reperfuse the
brain in most patients with large thrombi. In a Phase IIa
lowdose safety study (n=65), conducted by University of
TexasHouston, delivering Argatroban with rtPA indicated
that both drugs appear safe when delivered concomitantly
and recanalisation rates were greater than with historical
controls. The purpose of the trial is to estimate the overall
treatment benefit (improvement in disability) among
stroke patients treated with rtPA (Alteplase) who are
randomised to receive either lowdose Argatroban,
highdose Argatroban or neither. This study will provide
evidencebased hypotheses and data needed to design a
larger definitive trial. The study will be conducted in six
hospitals across the UK and will recruit males and females
over 18 years of age with acute ischemic stroke. During
the course of the treatment, patients will be evaluated via
CT angiogram, CT scans, vital signs, laboratory
measurements, and neurological and unctional outcomes.
Patients will also be evaluated at 24 hours following the
onset of the stroke, Day 7 or discharge (whichever comes
first) and at day 90.
Funding Body NIH USA
-3-
, Back to top
Study Title ECASS 4 Extend
European Cooperative Acute Stroke Study4: Extending
the time for Thrombolysis in Emergency Neurological
Deficits
Study Type Acute
Lay Summary The aim of this study is to assess the safety and
effectiveness of a drug called Alteplase in patients who
have suffered an ischaemic stroke. At the moment the
approved window following a stroke for Alteplase to be
administered is three hours. This is a short period and so
this study is looking at extending that time and establish
efficacy at 4.5 to 9 hours following onset, or following the
patient waking up with with symptoms of a stroke (wake
up stroke).
Funding Body Boehringer Ingelheim Ltd
-4-
Top of page
ACUTE research is when a patient admitted to hospital having had a stroke is asked to take
part in research that might involve a new stroke treatment.
ARTSS2
ECASS 4 Extend
ENCHANTED
EuroHYP-1
FOCUS
GOLD 2.2
LINCHPIN
MICA
PATCH
PISTE
RTEASE
TARDIS
TITCH 2
WAKE-UP
PREVENTION research increases understanding of what causes a stroke to happen and
improves the prevention of stroke in routine clinical practice – using a broad range of
research techniques.
CROMIS2
CVR Lacunar Stroke Study v1.0
ECST-2
Gluteal biopsy in CADASIL
RESTART
XILO-FIST - NEW
-1-
,REHABILITATION stroke studies aim to restore functional recovery and to facilitate patients
and their carers to lead the lives they wish.
ACCESS
BIG CACTUS
EVERLAP – NEW
Examining a 'life after stroke' help sheet for stroke survivors – NEW
Long term consequences and recovery from stroke: what is important to stroke survivors
and health professionals?
MELLO
NON INVASIVE BRAIN STIMULATION IN STROKE PATIENTS - NEW
OSPREy
RATULS
TEARS
TREAT UI
SOCLE II
-2-
,ACUTE STUDIES
Back to top
Study Title ARTSS2
A pilot, phase IIb, randomised, multi-center trial of
Argatroban in combination with recombinant tissue
plasminogen activator for acute stroke
Study Type Acute
Lay Summary A pilot, phase IIb, randomised, multicentre trial of
Argatroban in combination with recombinant tissue
plasminogen activator for acute stroke. Recombinant
tissue plasminogen activator (rtPA), the only proven
treatment for acute ischemic stroke, fails to reperfuse the
brain in most patients with large thrombi. In a Phase IIa
lowdose safety study (n=65), conducted by University of
TexasHouston, delivering Argatroban with rtPA indicated
that both drugs appear safe when delivered concomitantly
and recanalisation rates were greater than with historical
controls. The purpose of the trial is to estimate the overall
treatment benefit (improvement in disability) among
stroke patients treated with rtPA (Alteplase) who are
randomised to receive either lowdose Argatroban,
highdose Argatroban or neither. This study will provide
evidencebased hypotheses and data needed to design a
larger definitive trial. The study will be conducted in six
hospitals across the UK and will recruit males and females
over 18 years of age with acute ischemic stroke. During
the course of the treatment, patients will be evaluated via
CT angiogram, CT scans, vital signs, laboratory
measurements, and neurological and unctional outcomes.
Patients will also be evaluated at 24 hours following the
onset of the stroke, Day 7 or discharge (whichever comes
first) and at day 90.
Funding Body NIH USA
-3-
, Back to top
Study Title ECASS 4 Extend
European Cooperative Acute Stroke Study4: Extending
the time for Thrombolysis in Emergency Neurological
Deficits
Study Type Acute
Lay Summary The aim of this study is to assess the safety and
effectiveness of a drug called Alteplase in patients who
have suffered an ischaemic stroke. At the moment the
approved window following a stroke for Alteplase to be
administered is three hours. This is a short period and so
this study is looking at extending that time and establish
efficacy at 4.5 to 9 hours following onset, or following the
patient waking up with with symptoms of a stroke (wake
up stroke).
Funding Body Boehringer Ingelheim Ltd
-4-
